Cutaneous angiosarcoma

被引:119
作者
Mendenhall, William M.
Mendenhall, Charles M.
Werning, John W.
Reith, John D.
Mendenhall, Nancy P.
机构
[1] Univ Florida, Coll Med, Dept Radiat Oncol, Gainesville, FL USA
[2] Univ Florida, Coll Med, Dept Otolaryngol, Gainesville, FL USA
[3] Univ Florida, Coll Med, Dept Pathol, Gainesville, FL USA
[4] Phoobe Putney Mem Hosp, Dept Radiat Oncol, Albany, GA USA
来源
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS | 2006年 / 29卷 / 05期
关键词
angiosarcoma; surgery; radiotherapy; chemotherapy; LIPOSOMAL DOXORUBICIN; SCALP; RADIOTHERAPY; HEAD; DOCETAXEL; NECK; FACE;
D O I
10.1097/01.coc.0000227544.01779.52
中图分类号
R73 [肿瘤学];
学科分类号
100214 [肿瘤学];
摘要
Objective: To discuss the treatment and outcomes for cutaneous angiosarcoma. Methods: Review of the pertinent literature. Results: Cutaneous angiosarcoma is a rare, aggressive malignancy with a poor prognosis. It usually arises in the scalp or face and is locally advanced at presentation. Patients are most often white, male, and elderly. A subset of patients presents with multifocal disease and/or positive regional nodes. Although the optimal treatment is surgery followed by wide-field radiotherapy (RT), the disease is frequently so extensive at diagnosis that it is not completely resectable. Even after optimal local-regional treatment, there is a relatively high likelihood of a local recurrence at the margins of the RT fields. The probability of hematogenous dissemination is relatively high. Limited data suggest that chemotherapy may be useful for palliation with progression-free survival rates ranging from 1 to 5 months. The 5-year local-regional control rates are approximately 40% to 50%, the 5-year distant metastasis-free survival rates range from 20% to 40%, and the 5-year survival rates range from 10% to 30%. Conclusion: Cutaneous angiosarcoma is a rare, aggressive malignancy that is optimally treated with resection and wide-field postoperative RT. The likelihood of local-regional failure is high, as is the risk of distant relapse. Chemotherapy may be useful for short-term palliation.
引用
收藏
页码:524 / 528
页数:5
相关论文
共 31 条
[1]
Observations on angiopoietin 2 in patients with angiosarcoma [J].
Amo, Y ;
Masuzawa, M ;
Hamada, Y ;
Katsuoka, K .
BRITISH JOURNAL OF DERMATOLOGY, 2004, 150 (05) :1028-1029
[2]
Serum concentrations of vascular endothelial growth factor-D in angiosarcoma patients [J].
Amo, Y ;
Masuzawa, M ;
Hamada, Y ;
Katsuoka, K .
BRITISH JOURNAL OF DERMATOLOGY, 2004, 150 (01) :160-161
[3]
Treatment of scalp angiosarcoma by controlled perfusion of A-carotis externa with pegylated liposomal doxorubicin and intralesional application of pegylated interferon alfa [J].
Bong, AB ;
Bonnekoh, B ;
Schön, MP ;
Gollnick, H .
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2005, 52 (02) :S20-S23
[4]
DEYRUP AT, IN PRESS MOD PATHOL
[5]
Complete remission of a radio-resistant cutaneous angiosarcoma of the scalp by systemic treatment with liposomal doxorubicin [J].
Eiling, S ;
Lischner, S ;
Busch, JO ;
Rothaupt, D ;
Christophers, E ;
Hauschild, A .
BRITISH JOURNAL OF DERMATOLOGY, 2002, 147 (01) :150-153
[6]
A 14-year retrospective review of angiosarcoma: Clinical characteristics, prognostic factors, and treatment outcomes with surgery and chemotherapy [J].
Fury, MG ;
Antonescu, CR ;
Van Zee, KJ ;
Brennan, MF ;
Maki, RG .
CANCER JOURNAL, 2005, 11 (03) :241-247
[7]
Greene FL, 2002, AJCC CANC STAGING MA, P193
[8]
HODGKINSON DJ, 1979, CANCER-AM CANCER SOC, V44, P1106, DOI 10.1002/1097-0142(197909)44:3<1106::AID-CNCR2820440345>3.0.CO
[9]
2-C
[10]
HOLDEN CA, 1987, CANCER-AM CANCER SOC, V59, P1046, DOI 10.1002/1097-0142(19870301)59:5<1046::AID-CNCR2820590533>3.0.CO